Fig. 3

In vivo efficacy of KTC1101 in xenograft models. A Graphical representation of KTC1101’s residual percentage (area%) in the mouse liver microsome incubation system. B Graph showing the residual percentage (area) of KTC1101 in the mouse plasma incubation system. C Blood concentration–time curve following oral administration of KTC1101 (100 mg/kg) in mice. D Nude mice with subcutaneous tumors of PC3 cells were treated with either a vehicle or varying doses of KTC1101 (25, 50, or 100 mg/kg, PO) and ZSTK474 (200 mg/kg, PO) (n = 5). Tumors are presented post-excision. E–G Measurements of tumor volumes, tumor weights, and body weights every three days. H NSG mice with subcutaneous tumors of TMD8 cells were treated with either a vehicle or varying doses of KTC1101 (75, 100, or 125 mg/kg, PO), ZSTK474 (200 mg/kg, PO), and Copanlisib (14 mg/kg, IV) (n = 5). Images of excised tumors are presented. I-K Tracking of tumor volumes, tumor weights, and body weights at three-day intervals. L H&E staining and Immunohistochemistry staining of phosphorylated Akt (p-Akt) and Ki67 in PC3 tumor tissues from mouse xenografts treated with KTC1101 and ZSTK474. Scale bar, 200 μm. M Statistical quantification of staining intensities in (L), with each point representing the mean of 5 images. N H&E staining and Immunohistochemistry staining of phosphorylated Akt (p-Akt) and Ki67 in TMD8 tumor tissues from mouse xenografts treated with KTC1101, ZSTK474 and copanlisib. Scale bar, 200 μm. O Statistical quantification of staining intensities in (N), with each point representing the mean of 5 images. Graphs are presented as the mean ± SEM from three independent experiments; p-values were determined using a two-tailed unpaired Student’s t-test; *p < 0.05; **p < 0.01; ***p < 0.001